Slide 1: Corporate Briefing Session Q2 2022
CORPORATE BRIEFING SESSION Q2 - 2022
Slide 2: Corporate Information
CORPORATE INFORMATION Pattern of Shareholding Shariah Compliance Meezan Bank Limited reviewed the AitkenStuart Pakistan (Pvt.) accounts of AGP and found them to be in 55.80% Limited compliance with Karachi Meezan Islamic Index – 30 Criteria set out by Pakistan Stock Exchange. Muller & Phipps (Pakist
Slide 3: Board of Directors
BOARD OF DIRECTORS Mr. Tariq Moinuddin Khan Mr. Naved Abid Khan Mr. ZafarIqbal Sobani Mr. Kamran Nishat Chairman Independent Director Independent Director Non - Executive Director coir camara re Ms. Nusrat Munshi Mr. M. Kamran Mirza a ae ee CEO & Managing Director Non - Executive Director
Slide 4: Our Journey
OUR JOURNEY 1989 1991 1995 2003 2007 2013 Signs an Acquired 30% AGP (Pvt.) Ltd. Enters into a JV Purchase Eli Purchase UCB agreement with stake in Eli starts with Eli Lilly UCB Belgium Lilly brand brand rights for Lilly commercial Pakistan for to manufacture rights for Ceclor Rigix in operations cep
Slide 5: AGP Manufacturing Plants
AGP MANUFACTURING PLANTS Particulars Plant I Plant II Plant III [General Health Care] [Cephalosporin] [Nutraceuticals] Location Plot B-23/C, SITE, Plot D-109, SITE, F/46, SITE-II, Superhighway, Karachi Karachi Karachi Annual Production 35.4 Million packs 6.9 Million packs 1.1 Million Packs 2021 Area
Slide 6: Economic Indicators (Jan to July 2022 vs 2021)
ECONOMIC INDICATORS [JAN TO JULY 2022 VS 2021] CPI Inflation % KIBOR Month End Rate % 7M Avg 2022: 15.9% 7M Avg 2022: 12.6% 7M Avg 2021: 9.1% 7M Avg 2021: 8.8% 24.9 21.3 14.9 13.8 13.7 12.0 12.8 10.4 10.6 13.0 12.2 12.7 13.4 13.8 8.0 8.0 8.3 8.0 8.1 8.1 8.0 11.1 10.9 8.7 9.1 9.8 8.4 5.7 JAN FEB MAR
Slide 7: Pharma Industry Update
PHARMA INDUSTRY UPDATE INDUSTRY AGP OBS-AGP Consolidated IQVIA MOVING ANNUAL [AGP + OBS-AGP] TURNOVER MAT JUNE 2022 Total Revenue (PKR in Billion) 656.0 7.7 4.3 12.0 Value growth (%) Year to date 13.3 19.1 34.9 23.3 [June 2022] On consolidated level, ranking in terms of revenue stood at 17th positio
Slide 8: Highlights of Half Year Financial Statements 2022
HIGHLIGHTS OF HALF YEAR FINANCIAL STATEMENTS 2022 ALL NUMBERS ARE PKR IN MILLION EXCEPT FOR EARNING PER SHARE IN PKR [-------- STANDALONE --------] [-------- CONSOLIDATED --------] PARTICULARS Jun 2022 Jun 2021 Var % Jun 2022 Jun 2021 Var % Net Sales 4,899 3,647 34.3 7,124 3,647 95.3 Cost of Sales 2
Slide 9: AGP Standalone Performance Overview – Half Year 2022
AGP STANDALONE PERFORMANCE OVERVIEW – HALF YEAR 2022 PARTICULARS BAR GRAPHS REMARKS • AGP delivered an impressive top line performance of PKR 4,899 million • This resulted in a year-on-year (YoY) increase in the revenue by 34.3%, which is 4,899 mainly on the back of the growth of our top brands. SAL
Slide 10: AGP's Top Products Sales Overview
AGP’s TOP PRODUCTS SALES OVERVIEW On 12 Months basis, Rigix expected to reach Launched 5 brands consisting of 15 SKUs PKR 2 Billion milestone whereas Osnate and in Ortho, Neuro and Cardio segments. Ceclor are already in the PKR 1 Billion club. TOP PRODUCTS CONTRIBUTION TO SALES BRANDS JUNE 2022 (PKR
Slide 11: AGP's Top Products Market Overview
AGP’s TOP PRODUCTS MARKET OVERVIEW As per IQVIA, June 2022 Yearly Market Yearly Yearly YTD YTD YTD Brand Sales Share Molecule Value Sub TC Value % % % in Mn % in Mn in Mn Antihistamines Rigix 1,946 56.64 27.37 Cetirizine 3,436 21.21 9,796 19.19 Systemic Colecalciferol+ Colecalciferol+ Collagen Colla
Slide 12: OBS AGP's Top Products Overview
OBS AGP’s TOP PRODUCTS OVERVIEW Aligning focus on oral Antimicrobial On 12 Months basis, Azomax near the Penicillins and Oncology portfolio PKR 3 Billion milestone. SALES JUNE 2022 TOP PRODUCTS CONTRIBUTION TO SALES BRANDS (PKR IN MILLION) Others, Azomax 1,382 26.3% Amoxi Zatofen 189 clave, 3.1% Amo
Slide 13: OBS AGP's Top Products Market Overview
OBS AGP’s TOP PRODUCTS MARKET OVERVIEW As per IQVIA, June 2022 Yearly Market Yearly Yearly YTD YTD YTD Brand Sales Share Molecule Value Sub TC Value % % % in Mn % in Mn in Mn Systemic Azomax 2,807 34.18 42.10 Azithromycin 8,212 20.82 124,115 17.04 Antibacterial Anti-Asthma Zatofen 339 77.50 26.26 Ke
Slide 14: Overview of Financial Ratios
OVERVIEW OF FINANCIAL RATIOS Ratios 2022 2021 52.7 Ind. Avg.: 38.6 52.4 Ind. Avg.: 38.7 44.7 45.7 45.6 53.8 Gross Profit Ratio (%) 50.5 34.3 46.1 28.4 40.7 39.6 40.3 21.4 22.0 29.2 22.8 25.4 Ind. Avg.: 8.0 21.2 Ind. Avg.: 11.4 15.1 Net Profit to Sales Ratio (%) 13.9 12.2 15.8 12.5 13.8 9.1 10.8 10.7
Slide 15: Overview of Financial Ratios
OVERVIEW OF FINANCIAL RATIOS Ratios 2022 2021 Ind. Avg.: 15.5 Ind. Avg.: 17.0 24.1 27.2 EBIT Margin to Sales 20.3 19.7 17.6 21.7 22.5 16.7 18.8 14.1 16.8 15.5 Ratio (%) 11.4 15.1 7.5 8.0 9.0 6.7 Ind. Avg.: 14.3 35.7 Ind. Avg.: 20.8 Return on Equity* (%) 37.8 38.1 20.6 29.7 15.5 14.8 11.4 15.2 17.0 1
Slide 16: Overview of Financial Ratios
OVERVIEW OF FINANCIAL RATIOS Ratios 2021 2020 Ind. Avg.: 21.3 50.3 Ind. Avg.: 20.6 Price Earning Ratio* (Times) 67.0 31.5 27.3 26.9 16.6 16.9 21.3 12.2 14.0 13.2 15.5 9.9 10.9 10.0 13.0 11.4 9.2 *PE ratio is annualized
Slide 17: Recent Achievements
RECENT ACHIEVEMENTS AGP’s Annual Report 2020 secured 2nd position in the pharmaceutical sector in BCR Awards held jointly by ICAP and ICMAP Won awards in 6 different categories in the Global Diversity and Inclusion Benchmarks Conference and Awards 2021 GREEN 2nd Pharmaceutical in the industry to obt
Slide 18: Key Challenges
KEY CHALLENGES With current political and economic turmoil in the country, the cost of doing business is increasing. However, Company continuously monitors market and adopts best possible recourse to ensure smooth operations and minimize impact on profitability. CHALLENGES POTENTIAL IMPACT MITIGATIN
Slide 19: Future Outlook
FUTURE OUTLOOK HIGH POTENTIAL PRODUCTS NEW LAUNCHES Will continue to drive growth from high potential Focus on launching new and robust product products with high margins; pipeline and therapies; With the aim to increase market share and Over the last 5 years, the Company has launched penetrate furt
Slide 20: Environment, Health & Safety
ENVIRONMENT, HEALTH & SAFETY Donated various medicines Sponsored an annual scholarship [including Hepatitis-C PKR 69 fund at IBA to support promising million] to various renowned and underprivileged students. institutions. Initiated tree plantation campaign Donated to Ida Rieu Welfare under the them
Slide 21: Thank You
THANK YOU 21